Evidence map›Paper›PMID 39118235›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series.

Christelle Schofield, Dennis R Taaffe, Robert U Newton, Daniel A Galvão, Paul A Cohen, Jin-Soo Kim, Tarek Meniawy, Carolyn Peddle-McIntyre

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christelle SchofieldExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.ORCID 0000-0001-6322-0287
Dennis R TaaffeExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Robert U NewtonExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Daniel A GalvãoExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Paul A CohenSchool of Medicine, University of Western Australia, Crawley, Western Australia, Australia.
Jin-Soo KimExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Tarek MeniawySchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Carolyn Peddle-McIntyreExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.

Funding

Australian Government Research Training Program ScholarshipEdith Cowan University Ph.D. ScholarshipWestern Australian Cancer Council Ph.D. Top-up Scholarship
6 · The paper itself

Abstract

objectivesIn ovarian and other cancers, low muscle mass and density are associated with poorer clinical outcomes. However, screening for cancer-related sarcopenia (typically defined as low muscle mass) is not routinely conducted. The European Working Group on Sarcopenia in Older People (EWGSOP) recommends an algorithm for sarcopenia screening and diagnosis in clinical settings, with sarcopenia based on muscle strength and mass, and severity on physical performance. We explored the application of the EWGSOP2 algorithm to assess sarcopenia in six ovarian cancer patients receiving neoadjuvant chemotherapy.

methodsWe assessed sarcopenia risk with the SARC-F screening questionnaire (at risk ≥4 points), muscle strength with a handgrip strength test (cut point <16 kg) and five times sit-to-stand test (cut point >15 s), muscle mass by skeletal muscle index (SMI in cm

resultsOf six participants, none were identified as "at risk" for sarcopenia based on SARC-F scores. Two participants were severely sarcopenic based on EWGSOP2 criteria (had low muscle strength, mass, and physical performance), and five participants were sarcopenic based on muscle mass only. DISCUSSION: Ovarian cancer patients with low muscle mass during neoadjuvant chemotherapy may not be identified as sarcopenic based on the EWGSOP2 diagnostic algorithm. While lacking a universally accepted definition for cancer-related sarcopenia and cancer-specific recommendations for the screening, diagnosis, and treatment of sarcopenia, ovarian cancer clinicians should focus on the diagnosis and treatment of low muscle mass and density.

Indexed as

Neoadjuvant TherapyOvarian NeoplasmsSarcopeniaAgedAlgorithmsChemotherapy, AdjuvantFemaleHand StrengthHumansMiddle AgedMuscle, SkeletalMuscle StrengthNeoplasm Stagingmuscle massmuscle strengthovarian cancersarcopenia

Identifiers

PMID39118235
PMCPMC11310097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.